Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies

NCT06674538 is registered in ClinicalTrials.gov with Moonshot Antibodies as lead sponsor.

NCT NCT06674538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06674538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label Clinical Trial to Treat Stage IV Cancer Patients With Multiple Patient-specific Mutated Cell Surface Proteins With Chimeric Antibodies
Lead sponsor
Moonshot Antibodies
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
December 30, 2024
Completion date
January 31, 2029
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue cancer